Published in J Neuroinflammation on August 06, 2010
IDO expression in brain tumors increases the recruitment of regulatory T cells and negatively impacts survival. Clin Cancer Res (2012) 1.55
Using antimicrobial adjuvant therapy in cancer treatment: a review. Infect Agent Cancer (2012) 0.86
Pancreatic cancer: role of the immune system in cancer progression and vaccine-based immunotherapy. Hum Vaccin Immunother (2014) 0.84
1-Methyl-tryptophan attenuates regulatory T cells differentiation due to the inhibition of estrogen-IDO1-MRC2 axis in endometriosis. Cell Death Dis (2016) 0.75
Herpes Simplex Virus (HSV-1) Encephalitis Mimicking Glioblastoma: Case Report and Review of the Literature. J Clin Med (2014) 0.75
The effects of antiviral treatment on breast cancer cell line. Infect Agent Cancer (2017) 0.75
Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem (1998) 9.37
Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res (2009) 7.83
Antigen-dependent proliferation of CD4+ CD25+ regulatory T cells in vivo. J Exp Med (2003) 5.23
Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest (2007) 5.05
Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res (2002) 4.58
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc Natl Acad Sci U S A (2003) 4.18
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol (2006) 3.84
Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol (2003) 3.18
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol (2008) 2.55
Cutting edge: the Foxp3 target miR-155 contributes to the development of regulatory T cells. J Immunol (2009) 2.51
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res (2008) 2.15
Detection of human cytomegalovirus in different histological types of gliomas. Acta Neuropathol (2008) 1.94
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival. Cell Cycle (2009) 1.87
Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol (2009) 1.80
Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother (2007) 1.70
Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol (2009) 1.59
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis. Proc Natl Acad Sci U S A (2008) 1.58
Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials. PLoS One (2008) 1.49
Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med (2008) 1.48
Cutting edge: Autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol (2008) 1.43
Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. Int J Cancer (2000) 1.36
CD4+ CD25+ FoxP3+ T-cell infiltration and heme oxygenase-1 expression correlate with tumor grade in human gliomas. J Neurooncol (2007) 1.35
Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother (2009) 1.30
Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand (2010) 1.26
Anti-parasitic effector mechanisms in human brain tumor cells: role of interferon-gamma and tumor necrosis factor-alpha. Eur J Immunol (1996) 1.25
Glioblastoma-derived mechanisms of systemic immunosuppression. Neurosurg Clin N Am (2010) 1.22
Regulatory conversation between antigen presenting cells and regulatory T cells enhance immune suppression. Cell Immunol (2008) 1.22
IFN-gamma activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv Exp Med Biol (1999) 1.17
Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. BMC Cancer (2009) 1.14
Intra-tumoral dendritic cells increase efficacy of peripheral vaccination by modulation of glioma microenvironment. Neuro Oncol (2010) 1.13
Induction of toxoplasmostasis in a human glioblastoma by interferon gamma. J Neuroimmunol (1993) 1.11
CD4+ CD25+ Treg: divide and rule? Immunology (2004) 1.11
Immunosuppression via tryptophan catabolism: the role of kynurenine pathway enzymes. Transplantation (2007) 1.06
Emergence of cytomegalovirus disease in patients receiving temozolomide: report of two cases and literature review. Clin Infect Dis (2010) 0.97
Long-term adjuvant administration of temozolomide in patients with glioblastoma multiforme: experience of a single institution. J Cancer Res Clin Oncol (2010) 0.96
BM stromal cells ameliorate experimental autoimmune myasthenia gravis by altering the balance of Th cells through the secretion of IDO. Eur J Immunol (2009) 0.95
Cytokine mediated regulation of interferon-gamma-induced IDO activation. Adv Exp Med Biol (1999) 0.93
Recent advances in immunotherapy for human glioma. Curr Opin Oncol (2006) 0.90
Inhibition of group B streptococcal growth by IFN gamma-activated human glioblastoma cells. J Neuroimmunol (1998) 0.90
Impaired dexamethasone-mediated induction of tryptophan 2,3-dioxygenase in heme-deficient rat hepatocytes: translational control by a hepatic eIF2alpha kinase, the heme-regulated inhibitor. J Pharmacol Exp Ther (2007) 0.88
Dendritic cell immunotherapy for malignant gliomas. Rev Recent Clin Trials (2008) 0.82
Acyclovir clinical pharmacology. An overview. Am J Med (1982) 0.81
Mechanisms by which acyclovir reduces the oxidative neurotoxicity and biosynthesis of quinolinic acid. Life Sci (2006) 0.81
Glioblastoma: synergy of growth promotion between CCL5 and NK-1R can be thwarted by blocking CCL5 with miraviroc, an FDA approved anti-HIV drug and blocking NK-1R with aprepitant, an FDA approved anti-nausea drug. J Clin Pharm Ther (2010) 0.80
Aciclovir protects against quinolinic-acid-induced oxidative neurotoxicity. J Pharm Pharmacol (2005) 0.78
Acyclovir inhibits rat liver tryptophan-2,3-dioxygenase and induces a concomitant rise in brain serotonin and 5-hydroxyindole acetic acid levels. Metab Brain Dis (2008) 0.78
Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry (2009) 1.72
The atypical antipsychotic agents ziprasidone [correction of zisprasidone], risperdone and olanzapine as treatment for and prophylaxis against progressive multifocal leukoencephalopathy. Med Hypotheses (2005) 1.53
Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull (2010) 1.45
Disulfiram, a drug widely used to control alcoholism, suppresses the self-renewal of glioblastoma and over-rides resistance to temozolomide. Oncotarget (2012) 1.22
Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother (2006) 1.20
Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder. J Psychiatry Neurosci (2010) 1.19
Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder. Bipolar Disord (2012) 0.99
Neonatal infection with neurotropic influenza A virus induces the kynurenine pathway in early life and disrupts sensorimotor gating in adult Tap1-/- mice. Int J Neuropsychopharmacol (2009) 0.99
Effects of COX-1 and COX-2 inhibitors on the firing of rat midbrain dopaminergic neurons--possible involvement of endogenous kynurenic acid. Synapse (2006) 0.96
Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: implications for schizophrenia. Int J Neuropsychopharmacol (2008) 0.95
Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. J Psychiatry Neurosci (2012) 0.93
Crohn's disease remission on bupropion. Gastroenterology (2003) 0.92
Elevation of cerebrospinal fluid interleukin-1ß in bipolar disorder. J Psychiatry Neurosci (2011) 0.92
Temozolomide modifies caveolin-1 expression in experimental malignant gliomas in vitro and in vivo. Transl Oncol (2011) 0.90
Serotonin receptor 2A blocker (risperidone) has no effect on human polyomavirus JC infection of primary human fetal glial cells. J Neurovirol (2008) 0.90
Clozapine interacts with the glycine site of the NMDA receptor: electrophysiological studies of dopamine neurons in the rat ventral tegmental area. Life Sci (2008) 0.90
Activation of rat ventral tegmental area dopamine neurons by endogenous kynurenic acid: a pharmacological analysis. Neuropharmacology (2007) 0.88
Prenatal dexamethasone impairs behavior and the activation of the BDNF exon IV promoter in the paraventricular nucleus in adult offspring. Endocrinology (2008) 0.88
Tumor necrosis factor (TNF) can paradoxically increase on etanercept treatment, occasionally contributing to TNF-mediated disease. J Rheumatol (2007) 0.87
Combined inhibition of HER1/EGFR and RAC1 results in a synergistic antiproliferative effect on established and primary cultured human glioblastoma cells. Mol Cancer Ther (2013) 0.87
Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. Psychoneuroendocrinology (2012) 0.85
Temozolomide-induced modification of the CXC chemokine network in experimental gliomas. Int J Oncol (2011) 0.85
Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. J Neural Transm (Vienna) (2011) 0.84
Screening of anti-glioma effects induced by sigma-1 receptor ligands: potential new use for old anti-psychiatric medicines. Eur J Cancer (2009) 0.84
Tumor necrosis factor-alpha in hepatitis B: potential role for bupropion. J Hepatol (2003) 0.83
Cerebrospinal fluid kynurenic acid in male and female controls - correlation with monoamine metabolites and influences of confounding factors. J Psychiatr Res (2006) 0.83
How influenza's neuraminidase promotes virulence and creates localized lung mucosa immunodeficiency. Cell Mol Biol Lett (2006) 0.83
Artesunate enhances the antiproliferative effect of temozolomide on U87MG and A172 glioblastoma cell lines. Anticancer Agents Med Chem (2014) 0.82
Kynurenine 3-monooxygenase (KMO) polymorphisms in schizophrenia: an association study. Schizophr Res (2010) 0.82
Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha. J Rheumatol (2008) 0.82
Inhibitory action of clozapine on rat ventral tegmental area dopamine neurons following increased levels of endogenous kynurenic acid. Neuropsychopharmacology (2003) 0.81
Clozapine modulates midbrain dopamine neuron firing via interaction with the NMDA receptor complex. Synapse (2004) 0.80
Bupropion in psoriasis and atopic dermatitis: decreased tumor necrosis factor-alpha? Psychosom Med (2003) 0.80
Erlotinib in glioblastoma: lost in translation? Anticancer Agents Med Chem (2011) 0.80
Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression. Med Hypotheses (2005) 0.80
Bupropion for fatigue and as a tumor necrosis factor-alpha lowering agent in primary biliary cirrhosis. Med Hypotheses (2005) 0.79
Ritonavir and disulfiram have potential to inhibit caspase-1 mediated inflammation and reduce neurological sequelae after minor blast exposure. Med Hypotheses (2008) 0.78
Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question. Clin Transl Oncol (2009) 0.78
Role of the NMDA-receptor in Prepulse Inhibition in the Rat. Int J Tryptophan Res (2010) 0.77
Activation of noradrenergic locus coeruleus neurons by clozapine and haloperidol: involvement of glutamatergic mechanisms. Int J Neuropsychopharmacol (2005) 0.77
Review of evidence that posttransplantation psychiatric treatment commonly affects prolactin levels and thereby influences graft fate. Gen Hosp Psychiatry (2006) 0.76
Bupropion and chronic aphthous ulceration. Arch Dermatol (2005) 0.76
Dopamine agonists and valvular heart disease. N Engl J Med (2007) 0.76
H1-antihistamines. N Engl J Med (2005) 0.75
Glioblastoma: looking at the currently marketed sigma-1 agonists and antagonists. Neoplasia (2007) 0.75
Bupropion for Blau syndrome. Med Hypotheses (2004) 0.75
CSF kynurenic acid and suicide risk in schizophrenia spectrum psychosis. Psychiatry Res (2012) 0.75
Consideration of use of neuraminidase inhibitors such as oseltamivir and zanamivir in IgA nephropathy. Kidney Int (2005) 0.75
Paroxetine for hepatopulmonary syndrome? Med Hypotheses (2004) 0.75
Intraperitoneal lavage with imiquimod to eliminate epithelial ovarian cancer micro metastases. Med Hypotheses (2008) 0.75
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells: consideration of triamterene to treat lupus. Med Hypotheses (2010) 0.75
Regulatory effect of chemokines in bone marrow niche. Cell Tissue Res (2015) 0.75